Mineralocorticoids and outcome improvement in heart failure patients with and without atri

2,582 articles were screened to produce a meta-analysis of 5 randomized controlled trials on mineralocorticoid receptor antagonists (MRAs) in heart failure patients. The dataset contains pooled results, including a 34.5% prevalence of atrial fibrillation in the studied population and odds ratios for cardiovascular outcomes. It supports investigation into whether treatment benefits differ based on atrial fibrillation status and identifies potential moderators like sex and prior hospitalization.

Use Cases

• Assessing treatment effect heterogeneity based on atrial fibrillation status using pooled odds ratios
• Investigating demographic and clinical moderators (e.g., female sex, hypertension) via meta-regression results
• Estimating the prevalence of atrial fibrillation in heart failure trial populations
• Validating systematic review protocols for cardiovascular drug efficacy

Strengths

• Derived from a systematic review of 2,582 screened articles, ensuring a methodical evidence base
• Includes specific pooled statistics: 34.5% AF prevalence and odds ratios with confidence intervals
• Openly licensed (CC-BY-4.0), permitting reuse and redistribution

Limitations

• Column names and row count are not specified, limiting understanding of the data's granular structure
• Based on a meta-analysis of only 5 included studies, which may limit the generalizability of findings
• The dataset's underlying patient-level data is not available, only aggregated study results

Provenance

Source

Systematic search of MEDLINE and EMBASE databases, following PROSPERO protocol CRD420251007396

Collection Method

Meta-analysis and meta-regression of randomized controlled trials

Freshness

Last updated 2026-03-23